Would you use a NTRK TKI for a patient with metastatic HR+, HER2- breast cancer with a complex NTRK3 gene re-arrangement on Foundation testing?

While it's difficult to give an answer without knowing details of the fusion event, I would point to the potential for immunohistochemistry for Trk as an orthogonal method for identifying Trk expressing cancers with potential for testing Trk inhibitors. I would point to this paper for further inform...